The Evolving Role of Rapid-Acting Agents for the Treatment of MDD

The Evolving Role of Rapid-Acting Agents for the Treatment of MDD

The Evolving Role of Rapid-Acting Agents for the Treatment of MDD
RestartResume

Major depressive disorder leads global causes of disability, but treatment is evolving. Are your patients benefiting from new, rapid-acting agents? 

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Depression can cause a multitude of symptoms, many of which are associated with impairment that, if not treated appropriately, can go on for months or even years. With traditional antidepressants having a longer time to onset, the role of rapid-acting agents can greatly improve the quality of life for patients with major depressive disorder (MDD).  Dr. Michael Thase and Dr. Sagar Parikh discuss the clinical diagnosis of MDD and the role of emerging neuroactive steroids. Tune in and fasten your seat belt for faster results!

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Michael E. Thase, MD
    Professor of Psychiatry
    Perelman School of Medicine at the University of Pennsylvania
    Philadelphia, PA

    Research: Acadia, Inc.; Allergan, Inc.; AssureRx Health; Axsome Therapeutics, Inc.; BioHaven, Inc.; Johnson & Johnson; Otsuka Pharmaceutical Company, Ltd.; Patient-Centered Outcomes Research Institute (PCORI); Takeda Pharmaceutical Company, Ltd.
    Receives Royalties: American Psychiatric Foundation; Guilford Publications; Herald House; Wolters Kluwer; W.W. Norton & Company, Inc.
    Consulting Fees: Acadia, Inc.; Akili, Inc.; Alkermes PLC; Allergan, Inc., Axsome Therapeutics; Clexio Biosciences; Gerson Lehrman Group; H. Lundbeck, A/S; Janssen; Jazz Pharmaceuticals; Johnson & Johnson; Merck & Company, Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sage Pharmaceuticals; Seelos Pharmaceuticals; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Co., Ltd.
    Other (Spouse's Employment) - Peleton Advantage

    Faculty:
    Sagar V. Parikh, MD
    John F. Greden Professor of Depression and Clinical Neuroscience
    University of Michigan
    Ann Arbor, MI 

    Research: Janssen, Takeda, Sage
    Consulting Fees: Aifred, Janssen, Takeda, Sage, Mensante, Otsuka 

    Reviewers/Content Planners/Authors:

    • Libby Lurwick has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the clinical diagnosis of MDD and the impact of delayed or suboptimal treatment on patient outcomes
    • Discuss clinical considerations for the role of rapid-acting agents in the treatment of MDD
    • Explain the MOA of novel neuroactive steroids (NAS) for the treatment of MDD
  • Target Audience

    This activity is designed to meet the educational needs of psychiatrists, primary care physicians, nurse practitioners, physician assistants, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from Sage Therapeutics.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free